Morningstar‘s Stock Analysis OMMH
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile OMMH
Omnimmune Holdings Inc is a development-stage biotechnology company, which is engaged in integrating complementary cancer therapeutic, diagnostic and prognostic technologies.
Houston, TX, 77027
Competitors & Peers OMMH
Morningstar does not cover competitors or peers for this firm.
FAQs for Omnimmune Holdings Inc Stock
No. OMMH does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
OMMH’s market cap is 935.59.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
OMMH’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare OMMH’s historical performance against its industry peers and the overall market.